Abstract
Background Concurrent malignant brain tumors in patients with multiple sclerosis (MS) constitute a rare but paradigmatic phenomenon for studying neuroimmunological mechanisms from both molecular and clinical perspectives.
Methods A multicenter cohort of 26 patients diagnosed with both primary brain tumors and multiple sclerosis was studied for disease localization, tumor treatment-related MS activity, and molecular characteristics specific for diffuse glioma in MS patients.
Results MS neither predisposes nor protects from the development of gliomas. Patients with glioblastoma WHO grade IV without IDH mutations had a longstanding history of MS, whereas patients diagnosed with IDH-mutant astrocytoma WHO grade II received multiple sclerosis diagnosis mostly at the same time or later. Concurrent MS was associated with a lesser extent of tumor resection and a worse prognosis in IDH-mutant glioma patients (PFS 32 vs. 64 months, p=0.0206). When assessing tumor-intrinsic differences no distinct subgroup-defining methylation pattern was identified in gliomas of MS patients compared to other glioma samples. However, differential methylation of immune-related genetic loci including human leukocyte antigen locus on 6p21 and interleukin locus on 5q31 was found in MS patients vs. matched non-MS patients. In line, inflammatory disease activity increased in 42% of multiple sclerosis patients after brain tumor radiotherapy suggesting a susceptibility of multiple sclerosis brain tissue to pro-inflammatory stimuli such as ionizing radiation.
Conclusions Concurrent low-grade gliomas should be considered in multiple sclerosis patients with slowly progressive, expansive T2/FLAIR lesions. Our findings of typically reduced extent of resection in MS patients and increased MS activity after radiation inform future treatment decisions.
Key points
– Disease history and sequence of diagnosis differ in MS patients with high-vs low-grade glioma
– Gliomas of MS patients harbor subtle methylation changes in immune-related genetic regions
– Brain tumor radiotherapy is followed by MS disease activity
Importance of the study Immune escape is a hallmark of diffuse glioma, while inflammation is the underlying mechanism of multiple sclerosis. These opposing mechanisms concur in patients that suffer in parallel from multiple sclerosis and glioma. This study is the first to investigate the tumor characteristics, tumor treatment responses and effect on multiple sclerosis activity of a cohort of patients with both diseases. The data warrant caution in the interpretation of suspicious lesions in imaging and suggests risk loci for the observed detrimental effects of radiation specific to MS patients.
Introduction
Gliomas have been reported in patients with multiple sclerosis (MS) 1,2. As immune surveillance is critical in cancer development, a possible causal “immuno-genetic” relationship between neuroinflammatory diseases and malignant brain tumors has been repeatedly discussed 3. Proposed cancer-promoting mechanisms include a malignant transformation of multiple sclerosis plaques 4 and immunosuppression induced by immunomodulatory therapies 5,6,7. However, two population-based studies could not verify an altered risk for gliomas in patients with MS 8,9.
From a clinical perspective, concurrent brain tumors may interfere with the diagnosis and course of MS and vice versa. MS lesions can mimic cerebral malignancies in conventional magnetic resonance imaging (MRI) 10, and misdiagnosing brain tumor symptoms as relapse in patients with known MS can delay appropriate tumor treatment 2. Moreover, due to the limited number of cases and lack of detailed analyses of clinical and imaging disease patterns, outcome, and molecular profiling, little is known about the effects of radio- and chemotherapy on MS disease activity and progression.
Discovering the role of epigenetic regulations such as histone modification or DNA methylation for susceptibility, progression, and treatment response of brain tumors has resulted in a fundamental shift in molecular classification and subtyping 11,12. In contrast to distinct brain tumor methylomes, epigenetic changes in non-neoplastic diseases are subtler. In MS, aberrant DNA methylation patterns affect disease development and pathogenesis by mediating inflammatory response and neurodegeneration 13. Interestingly, methylation differences are not only seen in pathologically altered tissue but can also be recapitulated in normal-appearing white matter or peripheral blood cells of MS patients and mainly occur in immune-related genes 14.
While the failure of immune surveillance is crucial for pathogenesis in both conditions, the complex interplay between the immune microenvironment, genetic alterations, and epigenetic regulation is only partly understood.
In this study, we analyzed clinical, imaging, and molecular data of a multicenter cohort of 26 patients with MS and concurrent glioma to determine if brain tumors in MS patients are molecularly distinct and if concurrent MS affects tumor prognosis and occurrence of treatment-associated adverse events.
Materials and Methods
Study population
In this multicenter, retrospective analysis, we collected 30 brain tumor tissue samples diagnosed between 01 January 2001 and 31 December 2017 and clinical and radiographical data of patients with reported multiple sclerosis from the Departments of Neuropathology, Neurology and Neurosurgery, University of Heidelberg; the Departments of Neurology and Neurosurgery, University Medical Center Mannheim of Heidelberg University; Dr Senckenberg Institute of Neurooncology, University of Frankfurt, and the Department of Neurology, University of Tübingen (all located in Germany). Four cases were excluded due to tumor histology other than glioma or insufficient proof of multiple sclerosis diagnosis according to the revised McDonald criteria 15 resulting in a study population of 26 patients in the experimental cohort. Control cases with isocitrate dehydrogenase (IDH)-mutant 1p19q-intact astrocytoma WHO grade II or IDH-wildtype glioblastoma WHO grade IV were collected from the Departments of Neuropathology, Neurology, and Neurosurgery, University of Heidelberg, and matched for tumor histology and the known prognostic markers IDH- and O6-methylguanine-DNA methyltransferase (MGMT)-status, age at diagnosis, and Karnofsky-Index. Tissue sample collection and data collection and use were performed following local ethics regulations and approved by the local ethics committee (ethics votes 005/2003, 2013-832R-MA, 2018-614N-MA).
Clinical assessments
Progression-free survival (PFS), defined as the time from brain tumor surgery to the date of tumor progression, was assessed based on follow-up imaging performed under the response assessment in neuro-oncology (RANO) criteria 16,17. The overall survival (OS) was defined as the time from surgery to the date of decease. Multiple sclerosis disease activity was assessed based on clinical attacks and MRI follow-up according to the revised McDonald criteria 15.
Methylation analysis
Bioinformatic analysis of Illumina 450k methylation array data was performed with customized scripts adapted from the R (www.r-project.org) based library “ChAMP” (version: 2.10.116) as described previously 18. At the Genomics and Proteomics Core Facility of the German Cancer Research Center (DKFZ) in Heidelberg, Germany, the Infinium HumanMethylation450 BeadChip and kits (Illumina, San Diego, CA, USA) were used according to manufacturer’s instructions to obtain the DNA methylation status at >450,000 sites in paraffin-embedded tissue derived from glioma patients with MS and matched controls. Raw data was loaded using the load() function in “ChAMP”. For multi-hit sites, SNPs, and XY chromosome related CpGs data was filtered; next, data was normalized with a BMIQ based method and analyzed for batch effects with a singular value decomposition (SVD) algorithm. There was no significant batch to be corrected. Respective functions were used to assess differentially methylated regions (DMR). Principle component analysis was used for dimensionality reduction. Circos plots showing DMR distribution were constructed with the package “OmicCircos” (version: 1.26.0).
Statistical analyses
Logistic regression analyses to calculate odds ratios (ORs) with 95% confidence intervals (CIs) were performed to compare clinical characteristics in the experimental cohort and control cohort. Distribution of survival times was estimated by the Kaplan–Meier method and compared between groups with the log-rank test. A p-value of less than 0.05 was considered significant.
Data availability
Source code can be made available on reasonable request.
Results
Clinical characteristics of patients with multiple sclerosis and concurrent glioma
A multicenter, retrospective cohort of 26 patients with both MS and diffuse glioma, meeting the predefined inclusion criteria was assembled from four centers (Figure 1, Supplementary Table 1). A survey of 2809 brain tumor patients (C71 ICD-10-GM), diagnosed between 01 January 2007 and 31 December 2015, revealed no evidence of increased MS prevalence compared to published cohorts with or without autoimmune diseases (Anssar et al., 2020) (Supplementary Table 2). All gliomas had an astrocytic morphology, with IDH-mutant astrocytomas WHO grade II being the most frequent brain tumors in MS patients (46%), followed by IDH-wildtype glioblastomas WHO grade IV (31%). Median age at tumor diagnosis was 32.5 years for IDH-mutant astrocytomas and 59 years for glioblastomas, both within the age range expected for these tumor types 19 (Figure 2 A, Supplementary Table 3, 4). The mean age at MS diagnosis was 31 years and 40 years, respectively (Figure 2 B, Supplementary Table 5). The MS symptom course was relapsing-remitting in 19/26 (73%) cases and secondary progressive in 4/26 (15%). All patients had radiologically proven cerebral inflammatory lesions, 6/26 (23%) had spinal lesions, and 7/26 (27%) had optic neuritis. 15/26 (58%) patients received immunomodulatory treatment (Supplementary Table 1, Supplementary Figure 1 B).
While patients diagnosed with glioblastoma had a longstanding history of CNS inflammatory disease, patients diagnosed with IDH-mutant astrocytoma received MS diagnosis mostly at the same time or later. Subsequently, glioblastomas arose near existing inflammatory lesions, while IDH-mutant astrocytomas developed from radiologically normal-appearing white matter (NAWM) (Figure 2 D, E, F).
Concurrent multiple sclerosis diagnosis is associated with worse prognosis of IDH-mutant astrocytomas
Next, clinical data from glioma patients with concurrent MS were compared with data from control patients without MS and matched for tumor histology and the known prognostic markers IDH- and MGMT-status, age at diagnosis, and Karnofsky-Index (Supplementary Table 3, 4). The glioblastoma-related neurological symptoms and distinct radiological morphology led to prompt radiological tumor suspicion and subsequent histological diagnosis independent of MS comorbidity. In contrast, radiological findings in most MS patients with IDH-mutant astrocytoma WHO grade II occurred incidentally, with a median time of 21 months (0 – 68) between initial MRI suspicion and histological diagnosis (Figure 3 A, B). However, glioma size at the time of histological diagnosis was comparable between MS and control groups for both tumor types (Figure 3 C). For non-contrast enhancing lesions, results from non-invasive MRI spectroscopy could support tumor suspicion in one patient (Supplementary Figure 2). Glioma diagnosis was confirmed by biopsy in 14/26 (54%) cases, and 12/26 (46%) received partial or complete tumor resection. Remarkably, the proportion of patients receiving tumor biopsy was higher in MS patients than controls independent of tumor histology (29% vs. 14% for IDH-wildtype; 50% vs. 25% for IDH-mutant) (Figure 3 D). While all glioblastoma patients received standard tumor-specific treatment, except one non-MS patient receiving best supportive care, the majority of patients with IDH-mutant astrocytomas were primarily treated with a watchful waiting approach according to the current standard of care independent of MS diagnosis (Figure 3 E). As expected 20, patients with IDH-wildtype glioblastomas showed a significantly shorter PFS compared to patients with IDH-mutant astrocytomas independent of concurrent MS. Of note, multiple sclerosis was associated with a worse prognosis in IDH-mutant tumors only (PFS 32 vs. 64 months, p=0.0206) (Figure 3 F, Supplementary Figure 1 D). The limited sample size did not allow to firmly establish the impact of immunomodulatory treatments on brain tumor progression (Supplementary Figure 1 E).
Glioma radiotherapy as a possible risk factor for multiple sclerosis disease activity
The majority of patients were treated with radiotherapy (RT) alone or in combination with chemotherapy at one time during the course of brain tumor disease (83% in the IDH-mutant and 71% in the IDH-wildtype cohort) (Figure 4 A, Supplementary Figure 1 C). While none of the IDH-mutant astrocytoma patients showed clinical or radiological signs of multiple sclerosis disease activity according to NEDA-3 criteria within the 12 months prior to starting RT, 5/12 patients (42%) with multiple sclerosis and IDH-mutant astrocytoma showed disease activity within 12 months after RT, with an average of 1.4 clinical relapses. Remarkably, 89% of clinical episodes occurred within the first six months after RT and were associated with new contrast-enhancing lesions within or adjacent to the radiation field (Figure 4, Supplementary Figure 1 F). In 3/5 patients, radiation-associated neuroinflammation occurred despite immunomodulatory treatment, and in 2/5 patients, multiple sclerosis was initially diagnosed within six months after RT. Interestingly, one patient with IDH-wildtype glioblastoma experienced long-term survival with no evidence of tumor recurrence for eight years following radiation-induced pseudo-progression. The radiographical increase in disease activity was accompanied by neurological deterioration, leading to the initial diagnosis of a chronic progressive multiple sclerosis course eight months after completion of radiotherapy (Figure 5).
Genome-wide methylation analysis of glioma samples identified DMRs associated with neuroinflammation
Genome-wide methylation patterns of glioma tissue from 12 multiple sclerosis patients and the matched control cohort without multiple sclerosis were compared to address the question if chronic neuroinflammation may predispose susceptibility to the exacerbation of focal disease activity on a molecular level in multiple sclerosis patients after radiotherapy (Supplementary Table 3, 4). While principal component analysis and unsupervised clustering revealed no distinct subgroup-defining methylation pattern depending on multiple sclerosis diagnosis, analysis of DMRs identified 117 DMRs in IDH-mutant astrocytomas and 103 DMRs in IDH-wildtype glioblastomas, with 11 common DMRs possibly associated with multiple sclerosis (Figure 6 A, Supplementary Figure 3). Interestingly, DMRs build a hotspot on the short arm of chromosome 6 (p21.32) within the human leukocyte antigen (HLA) region (Figure 6 B). The HLA system plays a critical role in immune regulation by presenting epitopes to leukocytes and thereby releasing antigen-specific immune responses 21. For multiple sclerosis, the HLA system has been shown to comprise major susceptibility loci (Gourraud et al., 2012), and the aberrant methylation patterns of specific HLA genes in NAWM of multiple sclerosis patients are thought to be relevant for multiple sclerosis etiology (Huynh et al., 2014). Moreover, most known multiple sclerosis risk genes belong to the immune system, and genetic regions related to innate immunity are thought to constitute glioma risk factors (Plantone et al., 2015). In line, additional DMRs are located on chromosome 5q31 within the interleukin (IL) region and include genes associated with myelinization and immune function (Supplementary Table 6). These data suggest that epigenetic changes in inflammatory genes in NAWM predispose to exacerbation of neuroinflammation by focal irradiation.
Discussion
Multiple sclerosis with concurrent glioma is a rare phenomenon, with only a few cases reported 9,22-24. From an immunological perspective, both diseases comprise opposed paradigmatic conditions within the central nervous system (CNS), with excessive immune reactions causing multiple sclerosis and profound immunosuppression enabling glioma progression, respectively 25,26,27. The role of underlying onco-immunological mechanisms for disease susceptibility and etiology has been repeatedly discussed without answering the question of an incidental co-existence or causal relationship 22,28,3. In this context, epigenetic mechanisms could play an essential role. While region-specific changes in DNA methylation occur in multiple sclerosis brains 14, the methylome is known as a diagnostic and predictive factor in primary brain tumors 3,12. By comparative analysis of genome-wide DNA methylation patterns of gliomas occurring in patients with and without concurrent multiple sclerosis, we could identify DMRs involving immune-relevant genes such as HLA and interleukin regions (Figure 6). Although the pathophysiological relevance remains unproven, these results support previous findings of subtle but widespread and persistent epigenetic changes in the CNS tissue of multiple sclerosis patients 14 and could reflect underlying (subclinical) neuroinflammation.
One major clinical challenge is the accurate detection of brain malignancies in patients with known multiple sclerosis, where especially early non-enhancing gliomas could be misdiagnosed as multiple sclerosis lesions. On the other hand, tumefactive multiple sclerosis lesions can mimic brain tumors when viewed with conventional MRI techniques 2. In our cohort, the vast majority of IDH-mutant astrocytomas in patients suffering from multiple sclerosis were incidentally detected during routine radiological follow-up. Although an average of almost two years passed until histological validation was realized, MRI tumor size at the time of surgery was comparable to that of the control group in which further diagnostic procedures were triggered by neurological symptoms. Remarkably, a relevant proportion of multiple sclerosis patients received tumor biopsy only without further resection, which might have contributed to an unfavorable prognosis (Figure 3). Although the small sample sizes constitute a major limitation, our data suggest the importance of an additional diagnostic work-up, the early biopsy of atypical or suspicious lesions, and in case of a brain tumor diagnosis a second surgery to allow for (partial) resection as a known prognostic marker.
So far, little is known about the disease course of multiple sclerosis patients with concurrent brain tumors. While at the early stages of relapsing-remitting multiple sclerosis, clinical episodes associated with inflammatory lesions largely recover, incomplete recovery causes secondary disease progression over time 29. Although some case series suggest a positive impact of brain tumors on multiple sclerosis disease course 30, conclusive data including the role of brain cancer treatments and multiple sclerosis disease-modifying therapies are lacking. Our data support the concept of radiation-induced inflammation in multiple sclerosis, with close to half the patients presenting with clinical or radiological signs of disease activity after glioma radiotherapy, while showing no evident disease activity before radiotherapy (Figure 4). One patient experienced a complete long-term response after radiation-induced pseudo-progression (Figure 5). The role of secondary immune effects including release of tumor antigens for the response to radiotherapy is well known 31, and a combination of radiotherapy and immunotherapy has shown synergistic effects also in brain tumors 32. Thus, based on this paradigmatic concurrence of immunologically opposed CNS diseases, our data could support the concept of combined radioimmunotherapy to treat brain cancer.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Supplementary Material
Footnotes
Funding: This work was supported by a grant from the Deutsche Forschungsgemeinschaft (DFG) within CRC1366 “Vascular Control of Organ Function”, project number 39404578, to KS and MP (project C1) and the Hertie Foundation (P1200013) to KS. MOB acknowledges funding by the Else Kröner-Fresenius Stiftung (2019_EKMS.23).
Conflict of interest: The authors declare that they have no competing interests.
Authorship: Conception and design: KS, MP. Acquisition of data: all. Analysis of data: KS, TK, DS, FS, MP. Interpretation of data: all. Writing, review, and/or revision of the manuscript: all.
Abbreviations
- CI
- confidence interval
- DMP
- differentially methylated position
- DMR
- differentially methylated region
- HLA
- human leukocyte antigen
- IDH
- isocitrate dehydrogenase
- IL
- interleukin
- MGMT
- O6-methylguanine-DNA methyltransferase
- NAWM
- normal appearing white matter
- OR
- odds ratio
- OS
- overall survival
- PFS
- progression-free survival
- RANO
- response assessment in neuro-oncology
- RT
- radiotherapy
- SVD
- singular value decomposition